An infant case of pseudohypoaldosteronism type 1A caused by a novel NR3C2 variant

Saki Noda¹, Kohei Aoyama¹,², Yuto Kondo¹, Jun Okamura¹, Atsushi Suzuki², Naoya Yamaguchi², Aya Yoshida² and Yoshishige Miyake¹

© The Author(s) 2021

Pseudohypoaldosteronism type 1 (PHA1), first described in 1958, is a rare disease characterized by hyponatremia, hyperkalemia, and metabolic acidosis, despite elevated aldosterone levels. There are two existing forms of PHA1. PHA1B (MIM #264350) is dominant inheritance; it is caused by haploinsufficiency of the mineralocorticoid receptor (MR), which is encoded by NR3C2 on chromosome 4q31. The main symptoms of PHA1A are dehydration, vomiting, and failure to thrive. In PHA1A, aldosterone resistance is confined to the kidneys, and treatment with salt supplementation is generally unnecessary by the age of 1–3 years. Herein, we report a novel variant of NR3C2 in a Japanese infant and her father with PHA1A.

The patient was delivered by cesarean section at week 38 of gestation because of the pelvic position. Her body weight at birth was 2860 g. She was admitted to the hospital shortly after birth because of breathing problems and confirmed spontaneous pneumothorax. She was intubated from days one to six, and the infusion was terminated on day 11. She was discharged on day 17 after the child was extubated because of concerns about shock due to extreme lack of vigor, poor feeding, and electrolyte abnormalities. Results of endocrinological evaluation at the time of readmission confirmed extremely high levels of both plasma renin activity (319.2 ng/ml/h, mean ± standard deviation for the same age, 5.70 ± 2.97 ng/ml/h) and plasma aldosterone (30400.9 pg/ml, mean ± standard deviation for the same age, 381.6 ± 209.5 pg/ml). In addition, adrenocorticotropic hormone (ACTH) was 49.2 pg/ml (normal range, 7.2–63.3 pg/ml) and cortisol 36.3 μg/dl (normal range, 4.5–21.1 μg/dl) at that time; there was no evidence of decreased adrenal function. We diagnosed her with PHA1 and added oral salt (8.8 mEq/kg/d). After the child’s hospitalization for hyponatremia, a history of pseudohypoaldosteronism was revealed in her father, aunt, and paternal grandmother, all of whom had taken salt as infants (Fig. 1a). According to her father, he had never been diagnosed with hypertension during occupational health examinations. Although hyponatremia and hyperkalemia were observed from younger than 10 days of age at the time of her first admission (Fig. 1b), no further detailed examination was performed. Her serum sodium level returned to the normal range after starting oral salt therapy, and her body weight increased. Salt supplementation was discontinued when she was eight months old.

We obtained consent for NR3C2 gene analysis from her parents. The experimental protocols were approved by the Ethical Committee for the Study of Human Gene Analysis at Nagoya City University Graduate School of Medical Sciences (Control Number: 70-00-0200). We analyzed the NR3C2 gene and identified a novel heterozygous mutation of the splice donor site in IVS-2 (NM_000901.5: c.1757 + 1 G > C) in the splice donor site of IVS-2 in NR3C2.

Pseudohypoaldosteronism type 1A (PHA1A) is the renal form of pseudohypoaldosteronism with autosomal dominant inheritance. PHA1A is caused by haploinsufficiency of the mineralocorticoid receptor, which is encoded by NR3C2. We encountered an infant who was diagnosed with PHA1A due to hyponatremia, hyperkalemia, and poor weight gain in the neonatal period. She carried a novel heterozygous mutation (NM_000901.5: c.1757 + 1 G > C) in the splice donor site of IVS-2 in NR3C2.

Human Genome Variation; https://doi.org/10.1038/s41439-021-00173-7
we considered it an incidental complication. Adults with PHA1A spontaneous pneumothorax, but there are no similar reports, and unusual aspect of our PHA1A case was the complication of NR3C2 were observed younger than 10 days of age, though the data ruled out, even if there is a temporary increase in weight, such as cases, as in the present patient. Furthermore, PHA1A cannot be hyponatremia is observed in the neonatal period, even in mild interventions, such as prophylactic salt administration, when important to obtain a family history and provide appropriate poaldosteronism in the infant and her father was caused by this NR3C2 mutation.

PHA1A tends to have milder symptoms and a later onset than PHA1B. PHA1A is commonly diagnosed at approximately 2–4 weeks of age, sometimes within 10 days of age, because of failure to thrive. In our case, hyponatremia and hyperkalemia were observed younger than 10 days of age, though the data were obtained during the infusion, and hyponatremia progressed further after the infusion was stopped. NR3C2 mutations are inherited in approximately 70% of PHA1A cases, and de novo NR3C2 mutations are relatively rare. As unexplained early death in PHA1A families suggests that PHA1A may be fatal, it is important to obtain a family history and provide appropriate interventions, such as prophylactic salt administration, when hyponatremia is observed in the neonatal period, even in mild cases, as in the present patient. Furthermore, PHA1A cannot be ruled out, even if there is a temporary increase in weight, such as that observed during the first predischarge neonatal period. One unusual aspect of our PHA1A case was the complication of spontaneous pneumothorax, but there are no similar reports, and we considered it an incidental complication. Adults with PHA1A are considered to have lifelong elevated renin activity and high angiotensin 2 and aldosterone levels, yet they are clinically indistinguishable from unaffected individuals. Biochemical data for the adults in the family with this variant could not be evaluated in this study.

In conclusion, we identified a novel NR3C2 mutation in a PHA1A patient and reported the electrolyte course in the neonatal period.

HGV DATABASE
The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare. hgv.3106.

REFERENCES
1. Okeek, D. B. & Perry, J. W. A salt wasting syndrome in infancy. Arch. Dis. Child. 33, 252–256 (1958).
2. Gopal-Kothandapani, J. S. et al. Phenotypic diversity and correlation with the genotypes of pseudohypoaldosteronism type 1. J. Pediatr. Endocrinol. Metab. 32, 959–967 (2019).
3. Miklaszewksa, M. et al. Reference ranges and impact of selected confounders on classic serum and urinary renal markers in neonatal period. Adv. Med. Sci. 62, 143–150 (2017).
4. Rodriguez-Soriano, J., Ubeigoyena, M. & Vallo, A. Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children. Pediatr. Nephrol. 4, 105–110 (1990).
5. Kojima, S. (Plasma aldosterone concentrations and plasma renin activity according to age and their relationships with electrolytes of plasma and erythrocyte and oral sodium intake in normal neonates and children (author’s trans), Nihon Naibunpi Gakkai Zasshi 55, 1019–1037 (1979).
6. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
7. Belot, A. et al. Pseudohypoaldosteronism, report on a 10-patient series. Nephrol. Dial. Transpl. 23, 1636–1641 (2008).
8. Geller, D. S. et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J. Am. Soc. Nephrol. 17, 1429–1436 (2006).
9. Riepe, F. G. et al. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J. Clin. Endocrinol. Metab. 91, 4552–4561 (2006).
10. Pujo, L. et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum. Mutat. 28, 33–40 (2007).
11. Sarotaro, P. et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J. Clin. Endocrinol. Metab. 88, 2508–2517 (2003).

ACKNOWLEDGEMENTS
We are grateful to the patient and her family for participating in this study.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Kohei Aoyama.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Fig. 1  Pedigree diagram, electropherogram, and course of electrolytes. a Pedigree diagram. The patient’s grandmother, aunt, and father had a confirmed history of PHA1A, as represented by either dark squares (males) or circles (females). b Serum sodium and serum potassium levels in the neonatal period. c Results of Sanger sequencing for NR3C2 in the patient.
